Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs McCormick & Company, Incorporated (MKC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs McCormick & Company, Incorporated — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $299.01 (market cap $39.89B), while McCormick & Company, Incorporated trades at $52.88 (market cap $14.08B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 2.8× McCormick & Company, Incorporated's market cap, and McCormick & Company, Incorporated pays a 3.66% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | MKC | |
|---|---|---|
Market Cap | $39.89B | $14.08B |
Sector | Health | Consumer Staples |
52-Week High | $491.22 | $72.81 |
52-Week Low | $278.09 | $45.60 |
Enterprise Value | $38.15B | $18.68B |
Dividend Yield | — | 3.66% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
McCormick (MKC) trades at $52.45, up 1.77% on the day, with a bearish technical signal despite recent earnings beats. The stock shows strong profitability with a 21.91% net income margin and 25.7% ROE, supported by a transformative $45 billion Unilever Foods deal announced in July 2026. Valuation appears attractive with a P/E of 8.73, below industry averages, while cash flow trends indicate robust operational performance.
The outlook is mixed; analyst consensus targets $59.67 (14% upside) with a 'Hold' bias, but weak consumer volume growth and integration risks from the Unilever acquisition pose challenges. The stock offers a near 4% dividend yield, providing income support, yet execution on cost savings and volume recovery remains critical for sustained appreciation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About McCormick & Company, Incorporated
In its 130-year history, McCormick has grown to become the leading global manufacturer, marketer, and distributor of spices, herbs, extracts, seasonings, and other flavorings. Beyond end consumers, McCormick's customer base also includes top quick-service restaurants, retail grocery chains, and other packaged food and beverage manufacturers, with about 30% of sales generated beyond its home turf to include 150 other countries and territories. In addition to its namesake brand, the firm's portfolio includes Old Bay, Zatarain's, Thai Kitchen, Frank's RedHot, French's, and the recently acquired Cholula brand.
Read more on MKC →
